Literature DB >> 9155067

No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer.

T P Manolitsas, P Englefield, D M Eccles, I G Campbell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9155067      PMCID： PMC2228221          DOI： 10.1038/bjc.1997.238

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  12 in total

1.  Localization of the human progesterone receptor gene to chromosome 11q22-q23.

Authors:  M F Rousseau-Merck; M Misrahi; H Loosfelt; E Milgrom; R Berger
Journal:  Hum Genet       Date:  1987-11       Impact factor: 4.132

2.  Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion.

Authors:  S M Rowe; S J Coughlan; N J McKenna; E Garrett; D G Kieback; D N Carney; D R Headon
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

3.  Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator.

Authors:  B J Slotman; J J Nauta; B R Rao
Journal:  Cancer       Date:  1990-08-15       Impact factor: 6.860

4.  11q deletions in human colorectal carcinomas: cytogenetics and restriction fragment length polymorphism analysis.

Authors:  P L Keldysh; T A Dragani; E W Fleischman; L N Konstantinova; A G Perevoschikov; M A Pierotti; G Della Porta; B P Kopnin
Journal:  Genes Chromosomes Cancer       Date:  1993-01       Impact factor: 5.006

5.  Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24.

Authors:  G M Hampton; L A Penny; R N Baergen; A Larson; C Brewer; S Liao; R M Busby-Earle; A W Williams; C M Steel; C C Bird
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

6.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

7.  Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary.

Authors:  P Vierikko; A Kauppila; R Vihko
Journal:  Int J Cancer       Date:  1983-10-15       Impact factor: 7.396

8.  Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer.

Authors:  H Gabra; S P Langdon; J E Watson; R A Hawkins; B B Cohen; L Taylor; J Mackay; C M Steel; R C Leonard; J F Smyth
Journal:  Clin Cancer Res       Date:  1995-09       Impact factor: 12.531

9.  Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer.

Authors:  M Davis; A Hitchcock; W D Foulkes; I G Campbell
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

10.  Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3.

Authors:  G M Hampton; A Mannermaa; R Winqvist; M Alavaikko; G Blanco; P J Taskinen; H Kiviniemi; I Newsham; W K Cavenee; G A Evans; R Winquist
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701
View more
  18 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Genetic variation in the progesterone receptor gene and ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Patrick M Sluss; Daniel W Cramer
Journal:  Am J Epidemiol       Date:  2005-03-01       Impact factor: 4.897

3.  Analyze association of the progesterone receptor gene polymorphism PROGINS with ovarian cancer risk.

Authors:  Cunzhong Yuan; Cunfang Wang; Xiaoyan Liu; Beihua Kong
Journal:  Mol Biol Rep       Date:  2013-09-21       Impact factor: 2.316

4.  Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach.

Authors:  Eunjung Lee; Chris Hsu; Christopher A Haiman; Pedram Razavi; Pamela L Horn-Ross; David Van Den Berg; Leslie Bernstein; Loic Le Marchand; Brian E Henderson; V Wendy Setiawan; Giske Ursin
Journal:  Carcinogenesis       Date:  2010-06-13       Impact factor: 4.944

Review 5.  The loss of estrogen and progesterone receptor gene expression in human breast cancer.

Authors:  R G Lapidus; S J Nass; N E Davidson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

6.  Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies.

Authors:  Chen Zhou; Xiangman Zou; Xiaosha Wen; Zifen Guo
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

7.  Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies.

Authors:  Ting Liu; Lilan Chen; Xiangjun Sun; You Wang; Shu Li; Xia Yin; Xinran Wang; Chenhuan Ding; He Li; Wen Di
Journal:  Tumour Biol       Date:  2013-11-07

8.  Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population.

Authors:  Khadijeh Onsory; R C Sobti; Adnan Issa Al-Badran; Masatoshi Watanabe; Taizo Shiraishi; Awtar Krishan; Harsh Mohan; Pushpinder Kaur
Journal:  Mol Cell Biochem       Date:  2008-05-16       Impact factor: 3.396

9.  Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy.

Authors:  Anshika Srivastava; Kiran Lata Sharma; Neena Srivastava; Sanjeev Misra; Balraj Mittal
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

10.  A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer.

Authors:  Ella Thompson; Rebecca L Dragovic; Sally-Anne Stephenson; Diana M Eccles; Ian G Campbell; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2005-04-29       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.